BR112014013374B1 - Comprimidos de acamprosato e usos de acamprosato referência cruzada aos pedidos relacionados - Google Patents

Comprimidos de acamprosato e usos de acamprosato referência cruzada aos pedidos relacionados Download PDF

Info

Publication number
BR112014013374B1
BR112014013374B1 BR112014013374-3A BR112014013374A BR112014013374B1 BR 112014013374 B1 BR112014013374 B1 BR 112014013374B1 BR 112014013374 A BR112014013374 A BR 112014013374A BR 112014013374 B1 BR112014013374 B1 BR 112014013374B1
Authority
BR
Brazil
Prior art keywords
acamprosate
tablet
dose
drug
release
Prior art date
Application number
BR112014013374-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014013374A2 (pt
BR112014013374A8 (pt
Inventor
William D. Kerns
Barry S. Fogel
Kei-Lai Fong
San-Laung Chow
David Wong
Edward Lin
Original Assignee
Synchroneuron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synchroneuron Inc filed Critical Synchroneuron Inc
Publication of BR112014013374A2 publication Critical patent/BR112014013374A2/pt
Publication of BR112014013374A8 publication Critical patent/BR112014013374A8/pt
Publication of BR112014013374B1 publication Critical patent/BR112014013374B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014013374-3A 2011-12-02 2012-12-02 Comprimidos de acamprosato e usos de acamprosato referência cruzada aos pedidos relacionados BR112014013374B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161566550P 2011-12-02 2011-12-02
US61/566,550 2011-12-02
US201261649137P 2012-05-18 2012-05-18
US61/649,137 2012-05-18
PCT/US2012/067507 WO2013082573A1 (en) 2011-12-02 2012-12-02 Acamprosate formulations, methods of using the same, and combinations comprising the same

Publications (3)

Publication Number Publication Date
BR112014013374A2 BR112014013374A2 (pt) 2017-06-13
BR112014013374A8 BR112014013374A8 (pt) 2021-08-31
BR112014013374B1 true BR112014013374B1 (pt) 2022-10-11

Family

ID=48536156

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013374-3A BR112014013374B1 (pt) 2011-12-02 2012-12-02 Comprimidos de acamprosato e usos de acamprosato referência cruzada aos pedidos relacionados

Country Status (14)

Country Link
EP (1) EP2785337B1 (enExample)
JP (1) JP6407720B2 (enExample)
KR (1) KR102055859B1 (enExample)
CN (1) CN104379138B (enExample)
AU (1) AU2012345659B2 (enExample)
BR (1) BR112014013374B1 (enExample)
CA (1) CA2863265C (enExample)
HK (2) HK1207563A1 (enExample)
IL (1) IL232935B (enExample)
MX (1) MX375183B (enExample)
RU (1) RU2671399C2 (enExample)
SG (1) SG11201403785UA (enExample)
WO (1) WO2013082573A1 (enExample)
ZA (1) ZA201404826B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN105431144A (zh) 2013-06-05 2016-03-23 思康脑侒股份有限公司 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
WO2020206107A1 (en) * 2019-04-03 2020-10-08 Synchroneuron Inc. Formulations
US12260944B2 (en) * 2019-10-11 2025-03-25 Hoffmann-La-Roche Inc. Drug dosage determination devices and methods
IL304905A (en) * 2021-02-15 2023-10-01 Kymera Therapeutics Inc IRAK4 joints and their uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4562911B2 (ja) * 1998-01-13 2010-10-13 シンクロニュ−ロン，エルエルシ− 遅発性ジスキネジア及び他の運動障害の治療方法
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
MXPA04010956A (es) * 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
RU2284814C1 (ru) * 2005-04-08 2006-10-10 Государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства здравоохранения Российской Федерации" Способ лечения оптического неврита при оптикохиазмальном арахноидите в стадии ремиссии
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
WO2008073282A2 (en) * 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
EP2540294B1 (en) * 2010-02-22 2016-08-03 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
CN101987081B (zh) * 2010-07-16 2012-08-08 钟术光 一种控释制剂
CA2850468C (en) * 2010-09-28 2019-08-13 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract

Also Published As

Publication number Publication date
ZA201404826B (en) 2016-07-27
JP2015500812A (ja) 2015-01-08
IL232935A0 (en) 2014-07-31
CA2863265C (en) 2020-04-14
RU2014126879A (ru) 2016-01-27
KR102055859B1 (ko) 2019-12-13
AU2012345659A1 (en) 2014-07-24
IL232935B (en) 2020-11-30
CN104379138B (zh) 2021-12-07
AU2012345659B2 (en) 2017-09-28
EP2785337A4 (en) 2015-04-22
BR112014013374A2 (pt) 2017-06-13
EP2785337A1 (en) 2014-10-08
MX375183B (es) 2025-03-06
KR20140121394A (ko) 2014-10-15
WO2013082573A1 (en) 2013-06-06
SG11201403785UA (en) 2014-10-30
CN104379138A (zh) 2015-02-25
RU2671399C2 (ru) 2018-10-31
BR112014013374A8 (pt) 2021-08-31
JP6407720B2 (ja) 2018-10-17
HK1207563A1 (en) 2016-02-05
AU2012345659A8 (en) 2014-08-07
EP2785337B1 (en) 2021-01-20
MX2014006574A (es) 2015-02-10
HK1199841A1 (en) 2015-07-24
CA2863265A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
US10512621B2 (en) Methods of treating posttraumatic stress disorder with acamprosate salts
US20150250746A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
KR102624627B1 (ko) 지연 방출 데페리프론 정제 및 그의 사용 방법
AU2013290875A1 (en) Gastro-retentive drug delivery system
US20150202158A1 (en) Gastro-retentive drug delivery system
ES2408343A2 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
BRPI0611272A2 (pt) formulações de quinina
BR112014013374B1 (pt) Comprimidos de acamprosato e usos de acamprosato referência cruzada aos pedidos relacionados
TW200520748A (en) Modafinil modified release pharmaceutical compositions
US7235258B1 (en) Sustained-release formulations for treating CNS-mediated disorders
US20210154161A1 (en) Modified-release bucillamine compositions, kits, and methods for treating cystinuria, arthritis, gout, and related disorders
JP2016539171A (ja) アセブロフィリン及び疎水性徐放性基剤を含む徐放性薬学組成物
JP2003512311A (ja) Ｃｎｓ介在性障害を治療するための持続放出製剤
AU2018271336A1 (en) Pharmaceutical compositions comprising an S1P modulator
BR112019016091B1 (pt) Unidade de dosagem oral e uso de floroglucinol e trimetilfloroglucinol
HK1259508B (zh) 氘代多潘立酮组合物和用於治疗病症的方法

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 31/185 , A61K 9/20 , A61K 9/48 , A61P 25/00

Ipc: A61K 31/185 (2006.01), A61K 45/06 (2006.01), A61K

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/12/2012, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2701 DE 11/10/2022, QUANTO AO ITEM (54) TITULO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.